142 related articles for article (PubMed ID: 33124580)
1. Biosimilars and retention rates in patients with ankylosing spondylitis.
Pelechas E; Kaltsonoudis E; Voulgari PV; Drosos AA
Clin Exp Rheumatol; 2021; 39(2):440. PubMed ID: 33124580
[No Abstract] [Full Text] [Related]
2. Polychondritis in a Patient With Ankylosing Spondylitis on an Anti-TNF-α Biosimilar Agent.
Duro T; Li S; Jose D; Khawar T
J Clin Rheumatol; 2021 Dec; 27(8S):S656. PubMed ID: 35073638
[No Abstract] [Full Text] [Related]
3. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
Lindström U; Glintborg B; Di Giuseppe D; Nordström D; Aarrestad Provan S; Gudbjornsson B; Askling J; Lund Hetland M; Aaltonen K; Krogh NS; Geirsson AJ; Jacobsson LTH
RMD Open; 2019; 5(2):e001079. PubMed ID: 31749988
[TBL] [Abstract][Full Text] [Related]
4. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.
Park W; Yoo DH; Jaworski J; Brzezicki J; Gnylorybov A; Kadinov V; Sariego IG; Abud-Mendoza C; Escalante WJ; Kang SW; Andersone D; Blanco F; Hong SS; Lee SH; Braun J
Arthritis Res Ther; 2016 Jan; 18():25. PubMed ID: 26795209
[TBL] [Abstract][Full Text] [Related]
5. Assessment of effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting for treatment of patients with active rheumatoid arthritis or ankylosing spondylitis.
Codreanu C; Šírová K; Jarošová K; Batalov A
Curr Med Res Opin; 2018 Oct; 34(10):1763-1769. PubMed ID: 29439591
[TBL] [Abstract][Full Text] [Related]
6. Open-label non-mandatory transitioning from originators to biosimilars in routine clinical care.
Provenzano G; Arcuri C; Miceli MC
Clin Rheumatol; 2021 Jan; 40(1):425-427. PubMed ID: 32776313
[No Abstract] [Full Text] [Related]
7. Retention Rate and Efficacy of the Biosimilar CT-P13 Versus Reference Infliximab in Patients with Ankylosing Spondylitis: A Propensity Score-Matched Analysis from the Korean College of Rheumatology Biologics Registry.
Kim HA; Lee E; Lee SK; Park YB; Shin K
BioDrugs; 2020 Aug; 34(4):529-539. PubMed ID: 32696266
[TBL] [Abstract][Full Text] [Related]
8. Retention rate and long-term safety of biosimilar CT-P13 in patients with ankylosing spondylitis: data from the Korean College of Rheumatology Biologics registry.
Kim HA; Lee E; Lee SK; Park YB; Lee YN; Kang HJ; Shin K
Clin Exp Rheumatol; 2020; 38(2):267-274. PubMed ID: 31365335
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis.
Baji P; Péntek M; Szántó S; Géher P; Gulácsi L; Balogh O; Brodszky V
Eur J Health Econ; 2014 May; 15 Suppl 1(Suppl 1):S45-52. PubMed ID: 24832835
[TBL] [Abstract][Full Text] [Related]
10. A 5-year Retrospective Analysis of Drug Survival, Safety, and Effectiveness of the Infliximab Biosimilar CT-P13 in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis.
Kim TH; Lee SS; Park W; Song YW; Suh CH; Kim S; Lee YN; Yoo DH
Clin Drug Investig; 2020 Jun; 40(6):541-553. PubMed ID: 32328979
[TBL] [Abstract][Full Text] [Related]
11. Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study.
Benucci M; Gobbi FL; Bandinelli F; Damiani A; Infantino M; Grossi V; Manfredi M; Parisi S; Fusaro E; Batticciotto A; Sarzi-Puttini P; Atzeni F; Meacci F
Immunol Res; 2017 Feb; 65(1):419-422. PubMed ID: 27449503
[TBL] [Abstract][Full Text] [Related]
12. Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product.
Yoo DH; Oh C; Hong S; Park W
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S15-24. PubMed ID: 26395833
[TBL] [Abstract][Full Text] [Related]
13. [New and old therapeutic options in ankylosing spondylitis--is there an indication for sulfasalazine?].
Braun J; Sieper J
Z Rheumatol; 2002 Apr; 61(2):151-8. PubMed ID: 12056292
[No Abstract] [Full Text] [Related]
14. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
Braun J; Kudrin A
Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
[TBL] [Abstract][Full Text] [Related]
15. GP2015: An Etanercept Biosimilar.
Deeks ED
BioDrugs; 2017 Dec; 31(6):555-558. PubMed ID: 28940172
[TBL] [Abstract][Full Text] [Related]
16. Real-world observational study of biosimilars in inflammatory arthritis treatment: a systematic literature review.
Kim JW; Jung JY; Suh CH
Expert Opin Biol Ther; 2021 Jan; 21(1):57-73. PubMed ID: 32808557
[TBL] [Abstract][Full Text] [Related]
17. Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe.
Müller-Ladner U; Hong S; Oh C; Taylor P
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S5-14. PubMed ID: 26395832
[TBL] [Abstract][Full Text] [Related]
18. Quality of life and productivity loss in patients with ankylosing spondylitis using tumor necrosis factor inhibitors.
Ma KS; Kao PE; Chen KH; Liu CH
Int J Rheum Dis; 2023 Jul; 26(7):1412-1413. PubMed ID: 36941023
[No Abstract] [Full Text] [Related]
19. Effective serum level of etanercept biosimilar and effect of antidrug antibodies on drug levels and clinical efficacy in Chinese patients with ankylosing spondylitis.
Dong Y; Li P; Xu T; Bi L
Clin Rheumatol; 2019 Jun; 38(6):1587-1594. PubMed ID: 30747393
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of secukinumab treatment in a patient with ankylosing spondylitis and concomitant multiple sclerosis: a commentary.
Fonti GL; Chimenti MS; Greco E; Boffa L; Conigliaro P; Triggianese P; Perricone R
Clin Exp Rheumatol; 2021; 39(1):223. PubMed ID: 32452349
[No Abstract] [Full Text] [Related]
[Next] [New Search]
